JAK1 Inhibitor With Medicated Topical Therapy in Adolescents With Atopic Dermatitis
Status:
Completed
Trial end date:
2020-04-08
Target enrollment:
Participant gender:
Summary
This is a randomized, double blind, placebo controlled, parallel group, Phase 3 study to
evaluate the efficacy and safety of PF 04965842 in adolescent participants 12 to <18 years of
age with moderate to severe AD.